1
|
Luzak A, Karrasch S, Wacker M, Nowak D, Peters A, Schulz H. Sind Beeinträchtigungen der Lebensqualität (Dimensionen des EQ-5D) bereits bei Lungengesunden mit Lungenfunktion assoziiert (KORA F4L & Age). Das Gesundheitswesen 2017. [DOI: 10.1055/s-0037-1605787] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- A Luzak
- Institut für Epidemiologie I, Helmholtz Zentrum München – Deutsches Forschungszentrum für Gesundheit und Umwelt, Neuherberg
| | - S Karrasch
- Institut für Epidemiologie I, Helmholtz Zentrum München – Deutsches Forschungszentrum für Gesundheit und Umwelt, Neuherberg
- Institut und Poliklinik für Arbeits-, Sozial- und Umweltmedizin, Klinikum der Ludwig-Maximilians-Universität, München
| | - M Wacker
- Institut für Gesundheitsökonomie und Management im Gesundheitswesen, Helmholtz Zentrum München – Deutsches Forschungszentrum für Gesundheit und Umwelt, Neuherberg
| | - D Nowak
- Institut und Poliklinik für Arbeits-, Sozial- und Umweltmedizin, Klinikum der Ludwig-Maximilians-Universität, München
- Comprehensive Pneumology Center Munich (CPC-M), Mitglied des Deutschen Zentrums für Lungenforschung (DZL), München
| | - A Peters
- Institut für Epidemiologie II, Helmholtz Zentrum München – Deutsches Forschungszentrum für Gesundheit und Umwelt, Neuherberg
| | - H Schulz
- Institut für Epidemiologie I, Helmholtz Zentrum München – Deutsches Forschungszentrum für Gesundheit und Umwelt, Neuherberg
- Comprehensive Pneumology Center Munich (CPC-M), Mitglied des Deutschen Zentrums für Lungenforschung (DZL), München
| |
Collapse
|
2
|
Luzak A, Karrasch S, Thorand B, Nowak D, Holle R, Peters A, Schulz H. Is there an association between physical activity and lung function in lung-healthy German adults? – Results from the KORA FF4 study. Pneumologie 2017. [DOI: 10.1055/s-0037-1598414] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- A Luzak
- Institute of Epidemiology I, Helmholtz Zentrum München – German Research Center for Environmental Health
| | - S Karrasch
- Institute of Epidemiology I, Helmholtz Zentrum München – German Research Center for Environmental Health; Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, University Hospital of Munich (Lmu)
| | - B Thorand
- Institute of Epidemiology I, Helmholtz Zentrum München – German Research Center for Environmental Health
| | - D Nowak
- Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, University Hospital of Munich (Lmu); Comprehensive Pneumology Center Munich (Cpc-M), Member of the German Center for Lung Research
| | - R Holle
- Institute of Health Economics and Health Care Management, Helmholtz Zentrum München – German Research Center for Environmental Health
| | - A Peters
- Institute of Epidemiology I, Helmholtz Zentrum München – German Research Center for Environmental Health
| | - H Schulz
- Institute of Health Economics and Health Care Management, Helmholtz Zentrum München – German Research Center for Environmental Health
| |
Collapse
|
3
|
Karrasch S, Schäfer J, Kiehl G, Lucke T, Sußmann M, Luzak A, Ochmann U, Nowak D, Jörres RA, Vogelmeier C, Watz H, Schulz H. Accelerometric assessment of physical activity in COPD: Correlation between measures by two different devices. Pneumologie 2016. [DOI: 10.1055/s-0036-1584639] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
4
|
Gothe H, Schall I, Saverno K, Mitrovic M, Luzak A, Brixner D, Siebert U. The Impact of Generic Substitution on Health and Economic Outcomes: A Systematic Review. Appl Health Econ Health Policy 2015; 13 Suppl 1:S21-S33. [PMID: 26091709 PMCID: PMC4519629 DOI: 10.1007/s40258-014-0147-0] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
BACKGROUND Generic drugs are considered therapeutically equivalent to their original counterparts and lower in acquisition costs. However, the overall impact of generic substitution (GS) on global clinical and economic outcomes has not been conclusively evaluated. OBJECTIVE To test whether (1) generics and original products yield the same health outcomes, and (2) generic therapies save economic resources versus original therapies. METHODS We performed a systematic literature review in Medline, Embase, and the Cochrane Database of Systematic Reviews to identify original studies that examine clinical or economic outcomes of GS. After standardized data extraction, reported outcomes were categorized as supporting or rejecting the hypotheses. Each reported outcome was assessed and accounted for supporting and opposing GS. One publication could provide multiple outcome comparisons. RESULTS We included 40 studies across ten therapeutic areas. Fourteen studies examined patients on de novo therapy; 24 studies investigated maintenance drug therapy, and two studies considered both settings. Overall, 119 outcome comparisons were examined. Of 97 clinical outcome comparisons, 67% reported no significant difference between generic drugs and their off-patent counterparts. Of 22 economic comparisons, 64% suggested that GS increased costs. Consequently, hypothesis (1) was supported but hypothesis (2) was not. We found no major differences among studies that investigated clinical outcomes with de novo or maintenance therapy. CONCLUSION The review suggests that clinical effects are similar after GS. However, economic savings are not guaranteed. More systematic research comparing clinical and economic outcomes with or without GS is needed to inform policy on the use of generic substitution.
Collapse
Affiliation(s)
- H. Gothe
- />Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health and Health Technology Assessment, UMIT, University for Health Sciences, Medical Informatics and Technology, Eduard Wallnoefer Center 1, 6060 Hall i.T., Austria
- />Division of Public Health, Decision Modelling, Health Technology Assessment and Health Economics, ONCOTYROL, Center for Personalized Cancer Medicine Innsbruck, Karl Kapferer Strasse 5, 6020 Innsbruck, Austria
- />Dresden Medical School “Carl Gustav Carus”, Dresden University of Technology, Fetscherstraße 74, 01307 Dresden, Germany
| | - I. Schall
- />Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health and Health Technology Assessment, UMIT, University for Health Sciences, Medical Informatics and Technology, Eduard Wallnoefer Center 1, 6060 Hall i.T., Austria
| | - K. Saverno
- />Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health and Health Technology Assessment, UMIT, University for Health Sciences, Medical Informatics and Technology, Eduard Wallnoefer Center 1, 6060 Hall i.T., Austria
- />Department of Pharmacotherapy, University of Utah, 30 S 2000 E, Rm 4410, Salt Lake City, Utah 84112 USA
| | - M. Mitrovic
- />Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health and Health Technology Assessment, UMIT, University for Health Sciences, Medical Informatics and Technology, Eduard Wallnoefer Center 1, 6060 Hall i.T., Austria
| | - A. Luzak
- />Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health and Health Technology Assessment, UMIT, University for Health Sciences, Medical Informatics and Technology, Eduard Wallnoefer Center 1, 6060 Hall i.T., Austria
| | - D. Brixner
- />Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health and Health Technology Assessment, UMIT, University for Health Sciences, Medical Informatics and Technology, Eduard Wallnoefer Center 1, 6060 Hall i.T., Austria
- />Department of Pharmacotherapy, University of Utah, 30 S 2000 E, Rm 4410, Salt Lake City, Utah 84112 USA
| | - U. Siebert
- />Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health and Health Technology Assessment, UMIT, University for Health Sciences, Medical Informatics and Technology, Eduard Wallnoefer Center 1, 6060 Hall i.T., Austria
- />Center for Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115 USA
- />Institute for Technology Assessment, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 101 Merrimac St., 10th FL, Boston, MA 02114 USA
| |
Collapse
|
6
|
Glogger M, Schnell-Inderst P, Luzak A, Krueger A, Siebert U. New Reimbursement Schemes for Stratified Medicine in Oncology - A Systematic Review. Value Health 2014; 17:A663. [PMID: 27202420 DOI: 10.1016/j.jval.2014.08.2436] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Affiliation(s)
- M Glogger
- Ludwig Maximilian University of Munich, Munich, Germany
| | - P Schnell-Inderst
- UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i. T.; Innsbruck, Austria
| | - A Luzak
- UMIT - University ffor Health Sciences, Medical Informatics and Technology, Hall i. T., Austria
| | - A Krueger
- Ludwig Maximilian University of Munich, Munich, Germany
| | - U Siebert
- Medical Informatics and Technology, and Director of the Division for Health Technology Assessment and Bioinformatics, ONCOTYROL, Hall i. T, Austria
| |
Collapse
|